Skip to Content

Join the 'Afinitor' group to help and get support from people like you.

Afinitor News

New Drug Combo Shows Promise Curbing Tough-to-Treat Breast Cancer

Posted 16 hours ago by Drugs.com

THURSDAY, Dec. 8, 2016 – In women with a certain form of tough-to-treat breast cancer, treatment with a combination of two drugs appeared to keep the cancer at bay longer – from about five months to 10, a new study says. The cancer is known as "advanced hormone receptor positive, HER 2 negative" breast cancer. Women with these tumors are often given drugs called aromatase inhibitors, which work by reducing estrogen in the body and slowing the growth of the cancer. However, patients commonly develop resistance to aromatase inhibitor drugs, and they stop working. This is also known as endocrine therapy resistance. The new research may offer these patients some hope, researchers said. "Our study has shown that combining a newer medicine called everolimus [Afinitor] with a more established medicine, fulvestrant [Faslodex], has demonstrated benefit in aromatase inhibitor resistant breast ... Read more

Related support groups: Breast Cancer, Estradiol, Premarin, Ethinyl Estradiol, Estrace, Arimidex, Femara, Vagifem, Estrace Vaginal Cream, Vivelle, Breast Cancer, Metastatic, Anastrozole, Climara, Letrozole, Estring, Vivelle-Dot, Premarin Vaginal, Afinitor, Aromasin, Estradiol Patch

Kidney Cancer Drug Shows Promise in Early Trial

Posted 9 days ago by Drugs.com

WEDNESDAY, Nov. 30, 2016 – An experimental drug may show promise in treating kidney cancer, researchers say. The drug CB-839 is the first to target an enzyme that cancer cells require to stay alive, researchers said. This stage 1 clinical trial found that the drug was effective in most patients with advanced kidney cancer when used in combination with another cancer drug called everolimus (Afinitor, Zortress). In the 15 patients in the study, the dual treatment controlled tumors in 93 percent of the patients, who had either clear cell or papillary renal cell cancer. Tumors shrank by more than 30 percent in one patient, were stable in 13 patients, and grew by more than 20 percent in one patient. Clear cell is the most common form of kidney cancer, accounting for 75 percent of cases, the researchers said. All 12 patients with this type of kidney cancer had their disease controlled. ... Read more

Related support groups: Renal Failure, Renal Cell Carcinoma, Chronic Kidney Disease, Afinitor, Peritoneal dialysis, Renal Osteodystrophy, Everolimus, Zortress, Wilms' Tumor, Hyperphosphatemia of Renal Failure, Afinitor Disperz

Cancer's Heavy Financial Burden

Posted 8 Jun 2016 by Drugs.com

WEDNESDAY, June 8, 2016 – Many cancer patients can't afford to see their doctor or take the medications they've been prescribed, a new study finds. And the problem will likely only get worse as the cost of cancer treatments continues to rise, the study authors said. "You can prescribe the best drug in the world, but if patients can't afford it and they can't get it, then it won't be effective," said study author Dr. Greg Knight. He is chief fellow with the University of North Carolina School of Medicine's division of hematology and oncology. "We saw a significant portion of patients in our study who were stretching their prescriptions or not coming to the doctor's office," Knight said in a university news release. The researchers reviewed survey results from nearly 2,000 patients at the N.C. Cancer Hospital in Chapel Hill, N.C. The participants were all 18 and older, and had been ... Read more

Related support groups: Cancer, Breast Cancer, Prostate Cancer, Gleevec, Lung Cancer, Colorectal Cancer, Votrient, Brain Tumor, Avastin, Tarceva, Melanoma, Skin Cancer, Tasigna, Sutent, Ovarian Cancer, Afinitor, Endometrial Cancer, Sprycel, Herceptin, Nausea/Vomiting - Chemotherapy Induced

U.S. Pays Highest Prices for Cancer Meds: Study

Posted 6 Jun 2016 by Drugs.com

MONDAY, June 6, 2016 – The United States pays the highest prices in the world for generic and brand-name cancer drugs, a new study has found. However, as the world's wealthiest nation, the United States is better able to pay for those pricey drugs than poorer countries with somewhat lower medication prices, added study lead author Dr. Daniel Goldstein. People in China and India are much less able to afford cancer drugs than Americans, he said, even though U.S. monthly drug prices are about three to six times higher in the United States. That doesn't mean America came out on top in overall drug affordability, however. Developed nations such as Australia, England and Israel had the "best deal" in the world on cancer drugs, thanks to government programs that regulate drug pricing, the study found. "America is the wealthiest nation, but its drug prices are significantly higher – so much ... Read more

Related support groups: Cancer, Provera, Depo-Provera, Methotrexate, Breast Cancer, Accutane, Lupron, Tamoxifen, Medroxyprogesterone, Arimidex, Tretinoin, Fluorouracil, Lupron Depot, Femara, Gleevec, Lung Cancer, Colorectal Cancer, Isotretinoin, Rituxan, Claravis

FDA Approves Afinitor (everolimus) for Progressive, Nonfunctional Gastrointestinal and Lung Neuroendocrine Tumors (NET)

Posted 29 Feb 2016 by Drugs.com

EAST HANOVER, N.J., Feb. 26, 2016 Novartis today announced that the United States Food and Drug Administration (FDA) approved Afinitor (everolimus) tablets for the treatment of adult patients with progressive, well-differentiated, nonfunctional neuroendocrine tumors (NET) of gastrointestinal (GI) or lung origin that are unresectable, locally advanced or metastatic. Afinitor received a priority review designation providing a shortened review period for drugs that treat serious conditions and offer a significant improvement in safety or effectiveness. "Afinitor is the first treatment approved for progressive, nonfunctional NET of lung origin, and one of very few options available for progressive, nonfunctional GI NET, representing a shift in the treatment paradigm for these cancers," said Bruno Strigini, President, Novartis Oncology. "We are proud of our Afinitor development program, ... Read more

Related support groups: Afinitor, Everolimus, Neuroendocrine Carcinoma

Kidney Woes Tied to Raised Cancer Risk, Study Finds

Posted 12 Nov 2015 by Drugs.com

THURSDAY, Nov. 12, 2015 – Kidney failure and having a kidney transplant may increase the risk for certain types of cancer, a new study suggests. Poor kidney function and immune system-suppressing drugs may be behind this increased risk, according to Elizabeth Yanik, of the U.S. National Cancer Institute, and colleagues. For the study, published in the Nov. 12 online edition of the Journal of the American Society of Nephrology, the researchers looked at data from more than 200,000 U.S. kidney transplant candidates and recipients. Along with finding that these patients are at increased risk for certain types of cancer, the investigators also identified clear patterns of risk associated with different types of treatment. However, the associations seen in the study do not prove cause-and-effect. The risk of kidney and thyroid cancers was especially high when kidney failure patients were on ... Read more

Related support groups: Cancer, Methotrexate, Renal Failure, CellCept, Gilenya, Tysabri, Chronic Kidney Disease, Imuran, Xolair, Orencia, Revlimid, Arava, Leflunomide, Afinitor, Azathioprine, Tecfidera, Mycophenolate Mofetil, Peritoneal dialysis, Benlysta, Aubagio

New Immune-Focused Drug Shows Promise Against Advanced Kidney Cancer

Posted 25 Sep 2015 by Drugs.com

FRIDAY, Sept. 25, 2015 – A new drug that harnesses the power of the immune system to fight tumors appears to help people battling advanced kidney cancer, a new study finds. The drug, Opdivo (nivolumab), outperformed a standard chemotherapy, Afinitor (everolimus), in terms of shrinking tumors and boosting patient survival, the study found. The study was funded by Bristol-Myers Squibb, which makes Opdivo. It was to be presented Friday at the European Cancer Congress in Vienna, and is being published simultaneously in the New England Journal of Medicine. The new findings "are significant and clinically meaningful to patients and health care professionals alike," senior researcher Dr. Padmanee Sharma, of the University of Texas M.D. Anderson Cancer Center in Houston, said in a meeting news release. Sharma, a professor in the departments of genitourinary medical oncology and immunology, ... Read more

Related support groups: Renal Cell Carcinoma, Afinitor, Opdivo, Wilms' Tumor

U.S. Oncologists Decry High Cost of Cancer Drugs

Posted 23 Jul 2015 by Drugs.com

THURSDAY, July 23, 2015 – Soaring costs for cancer drugs are hurting patient care in the United States, a group of top oncologists claim. "High cancer-drug prices are affecting the care of patients with cancer and our health care system," Dr. Ayalew Tefferi, a hematologist at Mayo Clinic in Rochester, Minn., said in a Mayo news release. Tefferi and his colleagues made a number of recommendations on how to address the problem in a commentary published July 23 in the Mayo Clinic Proceedings. Allowing Medicare to negotiate drug prices is one of the suggestions the team of 118 leading cancer experts offered as a possible solution. Along with their recommendations, the group also expressed support for a patient-based grassroots movement on change.org that is demanding action on the issue. "The average gross household income in the U.S. is about $52,000 per year. For an insured patient with ... Read more

Related support groups: Cancer, Provera, Depo-Provera, Methotrexate, Breast Cancer, Accutane, Lupron, Prostate Cancer, Tamoxifen, Medroxyprogesterone, Arimidex, Tretinoin, Fluorouracil, Lupron Depot, Femara, Gleevec, Lung Cancer, Colorectal Cancer, Renal Cell Carcinoma, Isotretinoin

Medicines Are Biggest Culprit in Fatal Allergic Reactions: Study

Posted 10 Oct 2014 by Drugs.com

THURSDAY, Oct. 9, 2014 – Although food allergies have garnered a lot of attention lately, a new study reports that medications are actually the biggest cause of sudden deaths related to allergy. Over a little more than a decade, nearly 60 percent of the allergy-related deaths were caused by medications, while less than 7 percent were caused by food allergies, the study found. "Medications can be dangerous," said study researcher Dr. Elina Jerschow, director of the Drug Allergy Center at Montefiore Medical Center and assistant professor of medicine at Albert Einstein College of Medicine, in New York City. While research from other countries has reported medications as a major culprit in anaphylaxis-related deaths, Jerschow said, the problem has been less defined in the United States. One reason is that there is no national registry for anaphylaxis deaths, she said. The study was ... Read more

Related support groups: Provera, Depo-Provera, Amoxicillin, Metronidazole, Doxycycline, Cephalexin, Clindamycin, Penicillin, Methotrexate, Azithromycin, Bactrim, Cipro, Ciprofloxacin, Accutane, Augmentin, Levaquin, Lupron, Flagyl, Keflex, Zithromax

New Guidelines for Treating Form of Advanced Breast Cancer

Posted 2 Sep 2014 by Drugs.com

TUESDAY, Sept. 2, 2014 – A leading group of oncologists has released updated guidelines for the treatment of the major form of advanced breast cancer. HER2-negative breast tumors include cancers that don't respond to drugs that target the HER2 protein, the American Society of Clinical Oncology (ASCO) explained Tuesday in a news release. Almost 80 percent of women with advanced breast cancer have HER2-negative tumors, the group noted. "In releasing this guideline, our aim is to improve both the length and quality of patients' lives," Dr. Ann Partridge, co-chair of the expert panel that developed the guidelines, said in the statement. "Although no clear chemotherapy winner emerged – the guideline will help doctors and patients choose the best therapy based on what treatment would be most tolerable and convenient for the patient." The new guidelines were geared toward women with advanced ... Read more

Related support groups: Breast Cancer, Avastin, Afinitor, Aromasin, Exemestane, Bevacizumab, Everolimus, Zortress

Liver Cancer Drug Fails to Live Up to Early Promise

Posted 1 Jul 2014 by Drugs.com

TUESDAY, July 1, 2014 – Although it looked promising in early studies, the drug everolimus didn't improve survival for people with advanced liver cancer in its latest trial, a new study found. The findings from the phase 3 clinical trial are disappointing because earlier research suggested that everolimus (Afinitor) prevented tumor progression and improved survival for in advanced liver cancer. Normally, these patients can expect a median overall survival of less than one year. The only drug currently shown to significantly improve survival of advanced liver cancer patients is sorafenib (Nexavar). But that drug's benefits are temporary and the cancer eventually progresses, according to background information in the new study. The current study included 546 adults with advanced liver cancer whose disease progressed during or after treatment with sorafenib, or who could not take ... Read more

Related support groups: Afinitor, Nexavar, Sorafenib, Everolimus, Zortress, Hepatic Tumor

Cancer Chemotherapy Tied to Slight Rise in Risk for Leukemia

Posted 14 Feb 2013 by Drugs.com

THURSDAY, Feb. 14 – Chemotherapy can be a lifesaver for thousands of cancer patients, but a new study suggests that it might slightly raise the odds for a type of leukemia later in life. Over the past 30 years, the risk for acute myeloid leukemia (AML) has increased for patients who underwent chemotherapy for certain forms of cancer, particularly non-Hodgkin lymphoma, the new study found. On the other hand, the researchers from the U.S. National Cancer Institute said other cancer survivors may have a reduced risk for AML due to a change in chemotherapy agents that occurred decades ago. One expert not connected to the study stressed that cancer patients need to put the findings into perspective. "It's important to realize that the risk of developing acute myeloid leukemia related to prior chemotherapy is small and increases with the number of chemotherapy treatments given over time," ... Read more

Related support groups: Cancer, Provera, Depo-Provera, Methotrexate, Accutane, Lupron, Tamoxifen, Medroxyprogesterone, Arimidex, Tretinoin, Fluorouracil, Lupron Depot, Femara, Gleevec, Isotretinoin, Rituxan, Claravis, Votrient, Anastrozole, Avastin

FDA Approves Afinitor Disperz - First Drug Formulated for Children with Rare Brain Tumor

Posted 29 Aug 2012 by Drugs.com

The U.S. Food and Drug Administration today approved Afinitor Disperz (everolimus tablets for oral suspension), a new pediatric dosage form of the anti-cancer drug Afinitor (everolimus) used to treat a rare brain tumor called subependymal giant cell astrocytoma (SEGA). Afinitor Disperz is the first approved pediatric-specific dosage form developed for the treatment of a pediatric tumor. Afinitor Disperz is recommended to treat patients ages 1 year and older with tuberous sclerosis complex (TSC) who are diagnosed with SEGA that cannot be treated with surgery. Prior to approval of this new dosage form, Afinitor was recommended for use only in patients ages 3 years old and older. Afinitor was granted accelerated approval in 2010 to treat SEGA in patients with TSC. “Appropriate pediatric dosage forms, such as Afinitor Disperz, help to ensure the safe and effective use of oncology drugs in ... Read more

Related support groups: Brain Tumor, Afinitor, Everolimus

FDA Approves Afinitor for Advanced Breast Cancer

Posted 20 Jul 2012 by Drugs.com

July 20, 2012 – The U.S. Food and Drug Administration today approved Afinitor (everolimus) for use in combination with Aromasin (exemestane) to treat certain postmenopausal women with advanced hormone-receptor positive, HER2-negative breast cancer. The drug combination is intended for use in women with recurrence or progression of their cancer after treatment with Femara (letrozole) or Arimidex (anastrozole). Breast cancer is the second leading cause of cancer-related death among women. This year an estimated 226,870 women will be diagnosed with breast cancer, and 39,510 will die from the disease. “This is the first approval from the class of drugs known as mTOR inhibitors for the treatment of postmenopausal women with advanced hormone-receptor positive breast cancer,” said Richard Pazdur, M.D., director of the Office of Hematology and Oncology Products in the FDA’s Center for Dru ... Read more

Related support groups: Breast Cancer, Afinitor, Everolimus

Afinitor Approved for Advanced Breast Cancer

Posted 20 Jul 2012 by Drugs.com

FRIDAY, July 20 – Afinitor (everolimus) has been approved in combination with the drug exemestane to treat postmenopausal women with advanced hormone-receptor positive, HER2-negative breast cancer, the U.S. Food and Drug Administration said Friday. The newly approved combination is sanctioned for women whose cancer has progressed or returned despite previous use of the drugs letrozole (Femara) or anastrozole (Arimidex), the agency said in a news release. Breast cancer, the second-leading cause of cancer death among women, is expected to be newly diagnosed in an estimated 226,870 women this year and cause about 39,510 deaths, the FDA said. Afinitor – already sanctioned for uses including treating certain forms of advanced renal cell carcinoma – was clinically evaluated for the new use among 724 people with advanced breast cancer. People who took the combination drug had a 4.6-month ... Read more

Related support groups: Breast Cancer, Afinitor, Everolimus, Zortress

Page 1 2 Next

Ask a Question

Further Information

Related Condition Support Groups

Neuroendocrine Carcinoma, Brain Tumor, Breast Cancer, Tuberous Sclerosis, Pancreatic Cancer, Renal Angiomyolipoma, Subependymal Giant Cell Astrocytoma, Renal Cell Carcinoma

Afinitor Patient Information at Drugs.com